Hologic, Inc. (NASDAQ:HOLX) Director Lawrence M. Levy sold 9,596 shares of the firm’s stock in a transaction dated Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total transaction of $353,228.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Lawrence M. Levy also recently made the following trade(s):

  • On Thursday, September 7th, Lawrence M. Levy sold 7,139 shares of Hologic stock. The stock was sold at an average price of $39.04, for a total transaction of $278,706.56.

Shares of Hologic, Inc. (HOLX) traded down 0.27% during midday trading on Thursday, hitting $36.56. 1,751,177 shares of the company traded hands. Hologic, Inc. has a 52 week low of $35.15 and a 52 week high of $46.80. The stock has a 50 day moving average of $37.70 and a 200-day moving average of $41.98. The stock has a market capitalization of $10.25 billion, a PE ratio of 13.62 and a beta of 0.91.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.49 by $0.01. The company had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. Hologic had a net margin of 25.65% and a return on equity of 23.18%. Hologic’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the prior year, the business earned $0.51 earnings per share. Equities analysts forecast that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Hologic, Inc. (HOLX) Director Sells 9,596 Shares of Stock” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/12/insider-selling-hologic-inc-holx-director-sells-9596-shares-of-stock.html.

Several hedge funds have recently bought and sold shares of HOLX. Hall Laurie J Trustee grew its position in Hologic by 10.2% during the second quarter. Hall Laurie J Trustee now owns 2,425 shares of the medical equipment provider’s stock valued at $110,000 after acquiring an additional 225 shares during the last quarter. Commonwealth Bank of Australia grew its position in Hologic by 31.0% during the second quarter. Commonwealth Bank of Australia now owns 2,533 shares of the medical equipment provider’s stock valued at $114,000 after acquiring an additional 600 shares during the last quarter. MPS Loria Financial Planners LLC bought a new position in Hologic during the second quarter valued at approximately $191,000. National Asset Management Inc. bought a new position in Hologic during the second quarter valued at approximately $203,000. Finally, Miles Capital Inc. bought a new position in Hologic during the first quarter valued at approximately $206,000. Institutional investors own 96.38% of the company’s stock.

A number of equities analysts recently commented on the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $49.00 price target on shares of Hologic in a research report on Wednesday, June 28th. Bank of America Corporation reaffirmed a “neutral” rating and set a $48.00 price target (up from $44.00) on shares of Hologic in a research report on Friday, July 21st. Piper Jaffray Companies reaffirmed a “buy” rating and set a $51.00 price target on shares of Hologic in a research report on Friday, July 14th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Hologic in a research report on Friday, July 14th. Finally, BidaskClub lowered shares of Hologic from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, July 25th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and nine have issued a buy rating to the stock. Hologic has a consensus rating of “Hold” and a consensus price target of $47.77.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Insider Buying and Selling by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with MarketBeat.com's FREE daily email newsletter.